Clinical trials · Washington, D.C., DC
Solid Tumor Cancer clinical trials in Washington, D.C.
We’re tracking 264 recruiting solid tumor cancer studies with a site in or near Washington, D.C. — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT07416188RecruitingPhase 1/Phase 2
LMP744 drug for returning glioblastoma
This trial tests an experimental drug called LMP744 for people whose glioblastoma has come back. It aims to see if the drug can slow or stop tumor growth by targeting specific proteins in cancer cells.
Bethesda, MarylandAges 18–99 - NCT04222413RecruitingPhase 1
Study of metarrestin for advanced solid tumors
This study tests an experimental drug called metarrestin for people with solid tumors that have spread or come back after standard treatment. It may help by targeting a protein involved in cancer cell growth.
Bethesda, MarylandAges 12–120 - NCT06126276RecruitingPhase 2
Testing neratinib with or without palbociclib for HER2+ solid tumors
This trial tests two targeted drugs—neratinib alone or with palbociclib—for people with HER2-positive solid tumors (other than breast cancer) that have returned or not gone away. The goal is to see if blocking HER2 and CDK4/6 can shrink or slow the tumor.
Bethesda, MarylandAges 18 years+ - NCT02390752RecruitingPhase 1
Early drug study for children and young adults with hard-to-treat cancers
This Phase 1 trial tests pexidartinib (TURALIO) to see how safe it is and how well it works against refractory (hard-to-treat) leukemias and solid tumors, including tumors seen with NF1 and MPNST. It mainly helps researchers learn the best way to dose the medication and gather early signals of benefit.
Bethesda, MarylandAges 3–35 - NCT03340506RecruitingPhase 4
Follow-on treatment study for dabrafenib and trametinib
This study lets people who finished a prior dabrafenib/trametinib trial (sponsored by Novartis or former GSK) continue those medicines if the study doctor thinks it will help. It mainly focuses on ongoing treatment benefit rather than testing a new drug.
Bethesda, MarylandAges 18–100 - NCT06258304RecruitingPhase 1
Testing a new immunotherapy for advanced solid tumors
This trial tests a new immunotherapy drug, GIGA-564, for people with advanced solid tumors that have not responded to or have returned after standard treatments. The goal is to see if the drug is safe and effective, and to find the best dose.
Bethesda, MarylandAges 18 years+ - NCT05691517RecruitingPhase 1
Test drug CBX-12 in advanced cancers and monitor your response
This Phase 1 study tests how your body handles the drug CBX-12 in people with advanced solid cancers that have already tried prior treatments. It may help researchers learn safe dosing and how tumors respond, and you may be asked to provide biopsy samples.
Bethesda, MarylandAges 18 years+ - NCT06171750RecruitingPhase 1
Study of ANK-101 for advanced solid tumors
This trial tests a new drug, ANK-101, injected directly into tumors to help fight advanced solid tumors that have spread or can't be treated with standard therapies. It may be an option if you have a tumor that can be reached for injection.
Bethesda, MarylandAges 18 years+ - NCT06223542RecruitingPhase 1
TAK-243 for advanced cancers that haven't responded to other treatments
This trial tests a new drug called TAK-243 for people with advanced cancers (solid tumors or lymphomas) that have not responded to other treatments. It aims to see if the drug is safe and how well it works.
Bethesda, MarylandAges 18 years+ - NCT04074135RecruitingPhase 2
Study of pancreatic tumors in people with VHL
This trial studies the natural course and management of pancreatic neuroendocrine tumors in people with von Hippel–Lindau (VHL) disease. It may help doctors better predict how these pancreatic findings change over time and how to manage them.
Bethesda, MarylandAges 12 years+ - NCT04449549RecruitingPhase 2
Nilotinib and paclitaxel for rare solid tumors
This study tests a combination of two drugs, nilotinib and paclitaxel, in people with certain rare cancers that have not responded to standard treatments. It aims to see if this combination can shrink tumors or slow cancer growth.
Bethesda, MarylandAges 18–120 - NCT02154022Enrolling by invitation
Testing extra blood samples in patients with unexpected drug effects
This study collects extra lab samples from people already taking experimental or approved cancer treatments at NIH. It helps researchers understand why you may be having an unexpected response or side effects, and whether drug levels in the body might be the cause.
Bethesda, MarylandAges 2 years+ - NCT06774963RecruitingPhase 1
Study of LNCB74 for advanced solid tumors
This trial tests a new drug called LNCB74 for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective.
Falls Church, VirginiaAges 18 years+ - NCT06400472RecruitingPhase 1
Study of drug Sofe-M for advanced solid tumors
This trial tests a new drug (Sofe-M) for people with certain advanced solid tumors, including ovarian, endometrial, cervical, lung, breast, pancreatic, or colorectal cancers. The goal is to find the best dose and see how well it works, potentially offering a new treatment option.
Falls Church, VirginiaAges 18 years+ - NCT05579366RecruitingPhase 1/Phase 2
Study of rinatabart sesutecan for advanced solid tumors
This trial tests an investigational drug called rinatabart sesutecan (also known as Rina-S) for people with advanced solid tumors, including ovarian, endometrial, lung, breast, and other cancers. The drug is designed to target and kill cancer cells, and the study aims to see if it is safe and effective.
Rockville, MarylandAges 18 years+ - NCT05503797RecruitingPhase 2
Study of FORE8394 for cancers with BRAF changes
This trial tests a new drug, FORE8394, for people whose cancers have a change in the BRAF gene. It may be an option if you have a solid tumor or brain tumor that has not responded to other treatments.
Rockville, MarylandAges 8 years+ - NCT07749586RecruitingPhase 1/Phase 2
Study of ARV-6723 alone or with pembrolizumab for advanced solid tumors
This trial tests an experimental drug called ARV-6723, alone or with another drug called pembrolizumab, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if these combinations can help shrink tumors or slow their growth.
Fairfax, VirginiaAges 18 years+ - NCT06707610RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests a new drug called ALK202 for people with advanced solid tumors that have not responded to other treatments. The study aims to see if the drug is safe and to find the best dose.
Fairfax, VirginiaAges 18–75 - NCT07247110RecruitingPhase 1
Study of MK-4716 for people with certain solid tumors
This trial tests a new drug, MK-4716, alone or with cetuximab or pembrolizumab, for people with advanced solid tumors that have a specific KRAS gene change. It aims to see if the drug can shrink tumors or slow their growth.
Fairfax, VirginiaAges 18 years+ - NCT06892379RecruitingPhase 1
Study of HS-20110 for advanced solid tumors
This trial is testing a new drug called HS-20110 for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and can shrink tumors.
Fairfax, VirginiaAges 18 years+ - NCT06589596RecruitingPhase 1
Study of BGB-58067 for advanced solid tumors
This trial tests an experimental drug called BGB-58067, either alone or with other cancer treatments, for people with advanced solid tumors that have stopped responding to standard therapy. It may be an option if you have a specific genetic change (loss of MTAP) in your tumor.
Fairfax, VirginiaAges 18 years+ - NCT07174583RecruitingPhase 1/Phase 2
Study of IDE849 for DLL3-positive cancers like SCLC
This trial tests a new drug called IDE849 for cancers that make a protein called DLL3, including small cell lung cancer and some neuroendocrine tumors. It is for people whose cancer has progressed after standard treatments, and may be given alone or combined with other drugs like durvalumab or IDE161.
Fairfax, VirginiaAges 18 years+ - NCT07085091RecruitingPhase 1
Study of ALX2004 for advanced solid tumors
This trial tests a new drug, ALX2004, for people with certain advanced cancers (head and neck, lung, esophagus, or colorectal) that have stopped responding to standard treatments. The goal is to see if the drug is safe and effective.
Fairfax, VirginiaAges 18 years+ - NCT07223047RecruitingPhase 1/Phase 2
Study of BMS-986523 for advanced solid tumors with KRAS changes
This trial tests an experimental drug (BMS-986523) alone or with other cancer treatments for people with advanced solid tumors that have a specific change in the KRAS gene. It aims to see if the drug is safe and effective.
Fairfax, VirginiaAges 18 years+
Hear when a new Solid Tumor Cancer trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Solid Tumor Cancer trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting solid tumor cancer studies listed above.
- National Institutes of Health Clinical Center · 7 studies
- Inova Schar Cancer Institute · 3 studies
- National Cancer Institute · 2 studies
- National Cancer Institute Developmental Therapeutics Clinic · 2 studies
- NEXT Oncology · 2 studies
- NEXT Virginia · 2 studies
- ALX Center 2
- Clinical Trial Site
What taking part in a solid tumor cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there solid tumor cancer clinical trials near Washington, D.C.?
- Yes. We're currently tracking 264 recruiting solid tumor cancer studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a solid tumor cancer study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a solid tumor cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New solid tumor cancer studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.